Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Kromek Group plc ( (GB:KMK) ) has shared an announcement.
Kromek Group plc has issued 13,440,514 ordinary shares to Polymer N2 Ltd to settle accrued interest on a previously announced loan facility, which has now been repaid. The new shares will be admitted to trading on AIM, increasing the company’s issued share capital to 654,986,840 shares. This move reflects Kromek’s strategic financial management and could impact shareholder notifications under the Financial Conduct Authority’s rules.
Spark’s Take on GB:KMK Stock
According to Spark, TipRanks’ AI Analyst, GB:KMK is a Neutral.
The overall score of 56 reflects a stock with moderate strengths and notable challenges. Positive corporate events and technical indicators provide optimism, but ongoing financial and profitability issues weigh heavily on the score.
To see Spark’s full report on GB:KMK stock, click here.
More about Kromek Group plc
Kromek Group plc is a leading developer of radiation and bio-detection technology solutions for advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, with manufacturing operations in the UK and US, Kromek aims to enhance quality of life through innovative detection technology. The company serves medical, security, and industrial markets, providing detector components based on its cadmium zinc telluride (CZT) platform. In CBRN detection, Kromek offers nuclear radiation detection solutions for homeland defense and security, and is developing bio-security solutions for airborne pathogen detection.
Average Trading Volume: 963,537
Technical Sentiment Signal: Buy
Current Market Cap: £39.46M
For detailed information about KMK stock, go to TipRanks’ Stock Analysis page.